Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19

Combined Protection of Vaccination and Nirmatrelvir-Ritonavir Against Hospitalization in Adults With COVID-19

Abstract Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19–.24). Eligible adults, including th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical infectious diseases 2024-07, Vol.79 (1), p.108-110
Hauptverfasser: Shah, Melisa M, Joyce, Brendan, Plumb, Ian D, Sahakian, Sam, Feldstein, Leora R, Barkley, Eric, Paccione, Mason, Deckert, Joseph, Sandmann, Danessa, Hagen, Melissa Briggs, Gerhart, Jacqueline L
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Among adults at risk for severe coronavirus disease 2019 (COVID-19), the lowest hospitalization rate was among those who received nirmatrelvir-ritonavir after 3 or more messenger RNA vaccine doses (adjusted hazard ratio, 0.22; 95% confidence interval, .19–.24). Eligible adults, including those previously vaccinated, should be considered for COVID-19 antiviral treatment. Graphical abstract Graphical abstract This graphical abstract is also available at Tidbit: https://tidbitapp.io/tidbits/combined-protection-of-vaccination-and-nirmatrelvir-ritonavir-against-hospitalization-in-adults-with-covid-19
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciae105